Cover Image
Market Research Report

Europe Biochips Market Forecast 2019-2027

Published by Inkwood Research Product code 603656
Published Content info 87 Pages
Delivery time: 1-2 business days
Price
Back to Top
Europe Biochips Market Forecast 2019-2027
Published: March 9, 2019 Content info: 87 Pages
Description

KEY FINDINGS

Europe Biochips market stood at $XX million in 2018. By the end of the forecast period of 2019-2027, the market is anticipated to collect $XX million, exhibiting a CAGR of 20.22%. Germany, France, United Kingdom, Spain, Italy and the remaining countries forming the Rest of Europe regional segment are considered for the market analysis.

MARKET INSIGHTS

The biochips market in Europe is driven by government funding to develop and promote the biotechnology sector. Also, factors like increased government funding to develop personalized medicine and rising prevalence of various government initiatives supporting biotechnology are positively influencing the growth of the biochips market in Europe.

The German biochips market is being propelled by various government initiatives and programs to develop and promote biotechnology. On the other hand, the U.K biochip market finds several applications in molecular diagnostics, and in point-of-care diagnosis. France biochips market is mainly driven by funding supporting emerging fields such as cancer biomarkers, genomic studies and rise in diagnosis & treatment of cancer, while the Italian market is driven by rising investments in personalized medicines and genomics. The initiation of several government initiatives supporting biotechnology and technological advancements in biochip technology are driving the rapid integration of biochips technology in the market for the Rest of Europe regional segment.

COMPETITIVE INSIGHTS

Some of the competing players in this market are Cepheid Inc., Bio-Rad Laboratories Inc., bioMerieux SA, Cybrdi Inc., Merck GmbH, OriGene Technologies Inc., IMGENEX, PerkinElmer Inc., Biochain Institute Inc., Thermo Fisher Scientific Inc., Samsung Electronics Inc., Fluidigm Corporation, Gamida for Life Group, Illumina Inc. and Agilent Technology Inc.

Table of Contents
Product Code: 12922

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY & FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. DNA CHIPS ACCOUNTS FOR THE LARGEST REVENUE SHARE OF TYPE SEGMENT
    • 3.2.2. HOSPITALS & DIAGNOSTICS CENTERS - KEY END-USER VERTICAL
    • 3.2.3. PROTEIN CHIP TYPE IS PROJECTED TO RISE AT HIGHEST GROWTH RATE

4. MARKET DYNAMICS

  • 4.1. PARENT MARKET ANALYSIS: GENOMICS & PROTEOMICS MARKET
  • 4.2. ETYMOLOGY OF BIOCHIPS MARKET
  • 4.3. MARKET DEFINITION & SCOPE
  • 4.4. MARKET DRIVERS
    • 4.4.1. RISING INCIDENCES OF CANCER
    • 4.4.2. INCREASED GOVERNMENT FUNDING, R&D INVESTMENT IN BIOTECHNOLOGY
    • 4.4.3. GROWING INTEREST IN PERSONALIZED MEDICINES
    • 4.4.4. SIGNIFICANT GROWTH IN THE HEALTHCARE EXPENDITURE ACROSS GEOGRAPHIES
  • 4.5. MARKET RESTRAINTS
    • 4.5.1. LACK OF HEALTHCARE COVERAGE
    • 4.5.2. AVAILABILITY OF ALTERNATIVE TECHNOLOGY: NEXT GENERATION SEQUENCING (NGS) TECHNOLOGY
    • 4.5.3. LACK OF AWARENESS AMONG COMMON PEOPLE ABOUT BIOCHIP TECHNOLOGY
  • 4.6. MARKET OPPORTUNITIES
    • 4.6.1. TECHNOLOGICAL ADVANCEMENT IN THE BIOTECHNOLOGY
    • 4.6.2. GROWING APPLICATIONS OF BIOCHIPS
  • 4.7. MARKET CHALLENGES
    • 4.7.1. COMPLEXITY OF BIOLOGICAL SYSTEMS
    • 4.7.2. LACK OF COMMON REGULATORY STANDARDS
    • 4.7.3. HIGH INSTRUMENTATION COST

5. MARKET BY TYPE

  • 5.1. DNA CHIPS
    • 5.1.1. AGRICULTURAL BIOTECHNOLOGY
    • 5.1.2. CANCER DIAGNOSTICS & TREATMENT
    • 5.1.3. DRUG DISCOVERY
    • 5.1.4. GENE EXPRESSION
    • 5.1.5. GENOMICS
    • 5.1.6. SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING
    • 5.1.7. OTHER DNA CHIPS APPLICATIONS
  • 5.2. LAB ON A CHIP
    • 5.2.1. CLINICAL DIAGNOSTICS
    • 5.2.2. DRUG DISCOVERY
    • 5.2.3. GENOMICS
    • 5.2.4. POINT OF CARE (POC) & IN-VITRO DIAGNOSIS (IVS)
    • 5.2.5. PROTEOMICS
    • 5.2.6. OTHER LAB ON A CHIP APPLICATIONS
  • 5.3. PROTEIN CHIPS
    • 5.3.1. DIAGNOSTICS
    • 5.3.2. DRUG DISCOVERY
    • 5.3.3. EXPRESSION PROFILING
    • 5.3.4. HIGH THROUGHPUT SCREENING
    • 5.3.5. PROTEOMICS
    • 5.3.6. OTHER PROTEIN CHIP APPLICATIONS
  • 5.4. OTHER CHIPS
    • 5.4.1. CELL ARRAYS
    • 5.4.2. TISSUE ARRAYS

6. MARKET BY SUBSTRATE MATERIALS

  • 6.1. GLASS
  • 6.2. POLYMERS
  • 6.3. SILICON
  • 6.4. OTHER SUBSTRATE MATERIALS

7. MARKET BY END-USERS

  • 7.1. BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
  • 7.2. HOSPITALS & DIAGNOSTICS CENTERS
  • 7.3. ACADEMIC & RESEARCH INSTITUTE

8. KEY ANALYTICS

  • 8.1. PORTER'S FIVE FORCE MODEL
    • 8.1.1. THREAT OF NEW ENTRANTS
    • 8.1.2. THREAT OF SUBSTITUTE
    • 8.1.3. BARGAINING POWER OF SUPPLIERS
    • 8.1.4. BARGAINING POWER OF BUYERS
    • 8.1.5. THREAT OF COMPETITIVE RIVALRY
  • 8.2. OPPORTUNITY MATRIX
  • 8.3. VENDOR LANDSCAPE
  • 8.4. VALUE CHAIN ANALYSIS
    • 8.4.1. RESEARCH & DEVELOPMENT
    • 8.4.2. RAW MATERIALS
    • 8.4.3. MANUFACTURING
    • 8.4.4. WHOLESALERS/RETAILERS/DISTRIBUTORS
    • 8.4.5. END-USERS
  • 8.5. LEGAL, POLICY & REGULATORY FRAMEWORK
  • 8.6. KEY BUYING CRITERIA
    • 8.6.1. COST
    • 8.6.2. APPLICATIONS
    • 8.6.3. PRODUCT TYPE
  • 8.7. INVESTMENT ANALYSIS
    • 8.7.1. BY END-USERS
    • 8.7.2. BY BIOCHIPS TYPE

9. GEOGRAPHICAL ANALYSIS - EUROPE

  • 9.1. UNITED KINGDOM
  • 9.2. FRANCE
  • 9.3. GERMANY
  • 9.4. ITALY
  • 9.5. SPAIN
  • 9.6. REST OF EUROPE

10. COMPETITIVE LANDSCAPE

  • 10.1. MARKET SHARE ANALYSIS
  • 10.2. KEY COMPANY ANALYSIS
  • 10.3. CORPORATE STRATEGIES
    • 10.3.1. PARTNERSHIP & COLLABORATION
    • 10.3.2. MERGERS & ACQUISITIONS
  • 10.4. COMPANY PROFILES
    • 10.4.1. AGILENT TECHNOLOGY INC.
    • 10.4.2. BIOCHAIN INSTITUTE INC.
    • 10.4.3. BIOMERIEUX SA
    • 10.4.4. BIO-RAD LABORATORIES INC.
    • 10.4.5. CEPHEID INC.
    • 10.4.6. CYBRDI INC.
    • 10.4.7. FLUIDIGM CORPORATION
    • 10.4.8. GAMIDA FOR LIFE GROUP
    • 10.4.9. ILLUMINA INC.
    • 10.4.10. IMGENEX
    • 10.4.11. MERCK GMBH
    • 10.4.12. ORIGENE TECHNOLOGIES INC.
    • 10.4.13. PERKINELMER INC.
    • 10.4.14. SAMSUNG ELECTRONICS INC.
    • 10.4.15. THERMO FISHER SCIENTIFIC INC.

LIST OF TABLES

  • TABLE 1: EUROPE BIOCHIPS MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)
  • TABLE 2: NOTABLE INVESTMENTS MADE IN BIOTECHNOLOGY INDUSTRY IN 2017
  • TABLE 3: EUROPE BIOCHIPS MARKET, BY TYPE, 2019-2027, (IN $ MILLION)
  • TABLE 4: EUROPE DNA CHIPS MARKET, BY APPLICATIONS, 2019-2027 (IN $ MILLION)
  • TABLE 5: EUROPE LAB ON A CHIP MARKET, BY APPLICATIONS, 2019-2027 (IN $ MILLION)
  • TABLE 6: EUROPE PROTEIN CHIPS MARKET, BY APPLICATIONS, 2019-2027 (IN $ MILLION)
  • TABLE 7: EUROPE OTHER CHIPS MARKET, BY APPLICATIONS, 2019-2027 (IN $ MILLION)
  • TABLE 8: PROPERTIES OF BIOCHIPS SUBSTRATE MATERIALS
  • TABLE 9: EUROPE BIOCHIPS MARKET, BY SUBSTRATE MATERIALS, 2019-2027 (IN $ MILLIONS)
  • TABLE 10: EUROPE BIOCHIPS MARKET, BY END-USERS, 2019-2027 (IN $ MILLIONS)
  • TABLE 11: OPPORTUNITY MATRIX
  • TABLE 12: VENDOR LANDSCAPE
  • TABLE 13: LEGAL, POLICY & REGULATORY FRAMEWORK
  • TABLE 14: EUROPE BIOCHIPS MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)
  • TABLE 15: LIST OF PARTNERSHIP & COLLABORATION
  • TABLE 16: LIST OF MERGERS & ACQUISITIONS

LIST OF FIGURES

  • FIGURE 1: EUROPE BIOCHIPS MARKET, BY END-USER, 2018 & 2027 (IN %)
  • FIGURE 2: EVOLUTION & TRANSITION OF BIOCHIPS
  • FIGURE 3: WORLDWIDE HEALTHCARE SPENDING, BY REGIONS, 2014-2015 (% OF GDP)
  • FIGURE 4: COMPARISON OF HEALTHCARE SPENDING PER CAPITA & OUT OF THE POCKET HEALTH EXPENDITURE
  • FIGURE 5: EUROPE BIOCHIPS MARKET, BY DNA CHIPS, 2019-2027 (IN $ MILLION)
  • FIGURE 6: EUROPE DNA CHIPS MARKET, BY AGRICULTURAL BIOTECHNOLOGY, 2019-2027 (IN $ MILLION)
  • FIGURE 7: EUROPE DNA CHIPS MARKET, BY CANCER DIAGNOSTICS & TREATMENT, 2019-2027 (IN $ MILLION)
  • FIGURE 8: EUROPE DNA CHIPS MARKET, BY DRUG DISCOVERY, 2019-2027 (IN $ MILLION)
  • FIGURE 9: EUROPE DNA CHIPS MARKET, BY GENE EXPRESSION, 2019-2027 (IN $ MILLION)
  • FIGURE 10: EUROPE DNA CHIPS MARKET, BY GENOMICS, 2019-2027 (IN $ MILLION)
  • FIGURE 11: EUROPE DNA CHIPS MARKET, BY SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING, 2019-2027 (IN $ MILLION)
  • FIGURE 12: EUROPE DNA CHIPS MARKET, BY OTHER CHIPS, 2019-2027 (IN $ MILLION)
  • FIGURE 13: EUROPE BIOCHIPS MARKET, BY LAB ON A CHIP, 2019-2027 (IN $ MILLION)
  • FIGURE 14: EUROPE LAB ON A CHIP MARKET, BY CLINICAL DIAGNOSTICS, 2019-2027 (IN $ MILLION)
  • FIGURE 15: EUROPE LAB ON A CHIP MARKET, BY DRUG DISCOVERY, 2019-2027 (IN $ MILLION)
  • FIGURE 16: EUROPE LAB ON A CHIP MARKET, BY GENOMICS, 2019-2027 (IN $ MILLION)
  • FIGURE 17: EUROPE LAB ON A CHIP MARKET, BY POINT OF CARE (POC) & IN-VITRO DIAGNOSIS (IVS), 2019-2027 (IN $ MILLION)
  • FIGURE 18: EUROPE LAB ON A CHIP MARKET, BY PROTEOMICS, 2019-2027 (IN $ MILLION)
  • FIGURE 19: EUROPE LAB ON A CHIP MARKET, BY OTHER LAB ON A CHIP, 2019-2027 (IN $ MILLION)
  • FIGURE 20: EUROPE BIOCHIPS MARKET, BY PROTEIN CHIPS, 2019-2027 (IN $ MILLION)
  • FIGURE 21: EUROPE PROTEIN CHIPS MARKET, BY DIAGNOSTICS, 2019-2027 (IN $ MILLION)
  • FIGURE 22: EUROPE PROTEIN CHIPS MARKET, BY DRUG DISCOVERY, 2019-2027 (IN $ MILLION)
  • FIGURE 23: EUROPE PROTEIN CHIPS MARKET, BY EXPRESSION PROFILING, 2019-2027 (IN $ MILLION)
  • FIGURE 24: EUROPE PROTEIN CHIPS MARKET, BY HIGH THROUGHPUT SCREENING, 2019-2027 (IN $ MILLION)
  • FIGURE 25: EUROPE PROTEIN CHIPS MARKET, BY PROTEOMICS, 2019-2027 (IN $ MILLION)
  • FIGURE 26: EUROPE PROTEIN CHIPS MARKET, BY OTHER PROTEIN CHIPS, 2019-2027 (IN $ MILLION)
  • FIGURE 27: EUROPE BIOCHIPS MARKET, BY OTHER CHIPS, 2019-2027 (IN $ MILLION)
  • FIGURE 28: EUROPE OTHER BIOCHIPS MARKET, BY CELL ARRAYS, 2019-2027 (IN $ MILLION)
  • FIGURE 29: EUROPE OTHER BIOCHIPS MARKET, BY TISSUE ARRAYS, 2019-2027 (IN $ MILLION)
  • FIGURE 30: EUROPE BIOCHIPS MARKET, BY GLASS, 2019-2027 (IN $ MILLIONS)
  • FIGURE 31: EUROPE BIOCHIPS MARKET, BY POLYMERS, 2019-2027 (IN $ MILLIONS)
  • FIGURE 32: EUROPE BIOCHIPS MARKET, BY SILICON, 2019-2027 (IN $ MILLIONS)
  • FIGURE 33: EUROPE BIOCHIPS MARKET, BY OTHER SUBSTRATE MATERIALS, 2019-2027 (IN $ MILLIONS)
  • FIGURE 34: EUROPE BIOCHIPS MARKET, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, 2019-2027 (IN $ MILLIONS)
  • FIGURE 35: EUROPE BIOCHIPS MARKET, BY HOSPITALS & DIAGNOSTICS CENTERS, 2019-2027 (IN $ MILLIONS)
  • FIGURE 36: EUROPE BIOCHIPS MARKET, BY ACADEMIC & RESEARCH INSTITUTE, 2019-2027 (IN $ MILLIONS)
  • FIGURE 37: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 38: VALUE CHAIN ANALYSIS
  • FIGURE 39: KEY IMPACT ANALYSIS
  • FIGURE 40: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET IN 2018, BY END-USER
  • FIGURE 41: INVESTMENT OPPORTUNITIES IN BIOCHIPS MARKET IN 2018, BY TYPE
  • FIGURE 42: EUROPE BIOCHIPS MARKET, REGIONAL OUTLOOK, 2018 & 2027 (IN %)
  • FIGURE 43: UNITED KINGDOM BIOCHIPS MARKET, 2019-2027 (IN $ MILLION)
  • FIGURE 44: FRANCE BIOCHIPS MARKET, 2019-2027 (IN $ MILLION)
  • FIGURE 45: GERMANY BIOCHIPS MARKET, 2019-2027 (IN $ MILLION)
  • FIGURE 46: ITALY BIOCHIPS MARKET, 2019-2027 (IN $ MILLION)
  • FIGURE 47: SPAIN BIOCHIPS MARKET, 2019-2027 (IN $ MILLION)
  • FIGURE 48: REST OF EUROPE BIOCHIPS MARKET, 2019-2027 (IN $ MILLION)
  • FIGURE 49: MARKET SHARE ANALYSIS OF KEY PLAYERS IN 2018 (IN %)
Back to Top